COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Normal Binding of R-[11C]PK11195 in Human Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00205595
Recruitment Status : Unknown
Verified July 2008 by VU University Medical Center.
Recruitment status was:  Active, not recruiting
First Posted : September 20, 2005
Last Update Posted : July 8, 2008
Information provided by:
VU University Medical Center

Brief Summary:
This is a study using Positron Emission Tomography (PET) to study the normal distribution of the PET ligand (R)-[11C]PK11195. This ligand will be used to study inflammation in the brain in several brain disorders like Alzheimer's disease and traumatic brain injury.

Condition or disease Intervention/treatment Phase
Normal Aging Device: Positron Emission Tomography Phase 1

Detailed Description:

At the University Hospital Vrije Universiteit the PET ligand PK11195 labeled with carbon-11, (R)-[11C]PK11195, will be used to study microglia activation in-vivo in patients with traumatic brain damage, Alzheimer disease, multiple sclerosis and neuritis optica, disorders with unknown pathophysiology and treatment difficulties.

PK11195 (1-(2-chlorophenyl)-N-methyl-N-1(1-methylpropyl)-3 isoquinolinecarboxamide) is a highly specific ligand for the peripheral benzodiazepine-binding site, which is particularly abundant on cells of the mononuclear macrophage line (Myers et al., 1991). In normal human brain, the peripheral-type benzodiazepine receptor ligand PK11195 exhibits low to minimal binding primarily associated with the choroid plexus, ependymal linings and glial cells. However, following neuronal damage, the cells involved in the ensuing gliosis, microglia, show a marked increase in expression of these sites (Stephenson et al., 1995;Conway et al., 1998).

PK11195 labeled with carbon-11 is a PET ligand to peripheral type benzodiazepine receptors which has already been used in patients with stroke (Ramsay et al., 1992), Rasmussen's encephalitis (Banati et al., 1999), multiple sclerosis (Banati et al., 1997) and facial nerve lesions (Myers et al., 1999). However, no tracer kinetic model for quantification has been fully validated for(R)-[11C]PK11195. In order to use (R)-[11C]PK11195 for PET-imaging of microglia activation and to use it in the longitudinal monitoring of disease progression, baseline levels of ligand uptake in a healthy control population are required. This study aims to measure (R)-[11C]PK11195 uptake in normal brain in different age groups and to develop methods for quantification of specific binding of (R)-[11C]PK11195. Because (R)-[11C]PK11195 uptake depends on regional bloodflow, each (R)-[11C]PK11195 scan will be preceded by a cerebral bloodflow scan with H215O.


  • Determine the distribution of (R)-[11C]PK11195 in normal brain
  • Develop methods for quantification of specific binding of (R)-[11C]PK11195
  • Determine the metabolic profile of (R)-[11C]PK11195 in healthy volunteers

DESIGN OF THE STUDY Forty healthy subjects will be recruited, 20 males and 20 females. This is an open study. The study consists of one PET scan, which will be performed at the Department of Nuclear Medicine & PET research of the VU University Medical Centre.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Distribution and Quantification of Specific Binding of the Positron Emission Tomography Tracer R)-[11C]PK11195 in Normal Human Subjects
Study Start Date : February 2001
Study Completion Date : January 2007

Primary Outcome Measures :
  1. specific binding of tracer depending on age

Secondary Outcome Measures :
  1. tracer kinetic method

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and female subjects
  • Good physical and mental Health which will be evaluated with medical history, a physical examination and screening laboratory tests (see appendix 1).
  • Age between 18 and 40 years (20 subjects) and between 40 and 80 years (20 subjects).
  • Mini Mental State score >27
  • Body Mass Index (B.M.I.) between 20 -25.
  • Written informed consent of the subject.
  • Hb must be >8 mmol \ liter at the time of the screening.

Exclusion Criteria:

  • Previous neurotrauma with loss of consciousness
  • Any clinical significant abnormality of any clinical laboratory test, including drug screening, or ECG abnormality.
  • History of hypertension
  • Any subject who has received any investigational medication within 30 days prior to the start of this study, or who is scheduled to receive an investigational drug.
  • History of psychiatric or neurological illness
  • History of psychiatric or neurological illness in first-degree relatives
  • History of alcohol and/or drug abuse (DSM-IV criteria)
  • Current use of any medication
  • Blood donation within 3 months before the scan day
  • Claustrophobia
  • Metal objects in or around the body (braces, pacemaker, metal fragments);

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00205595

Layout table for location information
VU University Medical Centre
Amsterdam, Netherlands, 1081 HV
Sponsors and Collaborators
VU University Medical Center
Layout table for investigator information
Principal Investigator: Bart van Berckel, MD; PhD VUmc Medical Centre

Layout table for additonal information Identifier: NCT00205595    
Other Study ID Numbers: 2001/001
no other ID's
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: July 8, 2008
Last Verified: July 2008
Keywords provided by VU University Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
PK 11195
Antineoplastic Agents